

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
Group Art Unit - Unknown

#3

In re

Patent Application of

Yung-Hi Kim, et al.

Application No. Unknown

Confirmation No.: Unknown

Filed: September 24, 2004

Examiner: Unknown

"NOVEL THERAPEUTICAL USE OF  
AGONIST LIGANDS SPECIFIC TO G2A  
RECEPTOR"

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 CFR §1.97(b)

Box PCT  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The Examiner's attention is directed to the references which are listed on the attached Form PTO/SB/08A and/or PTO/SB/08B and copies of which are attached.

Citation of these references is respectfully requested.

No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate.

Respectfully submitted,



Teresa J. Welch  
Reg. No. 33,049

File No. OPA9408-32/US

Michael Best & Friedrich LLP  
One South Pinckney Street  
P. O. Box 1806  
Madison, WI 53701-1806  
(608) 257-3501  
Q:\firm\000000\0821\B0425415.DOC

DT Rec'd PCT/PTO 24 SEP 2004

PTO/SB/08A

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>	
			Application Number	Unknown 10/509300
			Filing Date	September 24, 2004
			First Named Inventor	Yung-Hi Kim
			Group Art Unit	Unknown
			Examiner Name	Unknown
Sheet 1 of 1	Attorney Docket Number		OPA9408-32/US	

U.S. PATENT DOCUMENTS				
Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
		6,207,412	Weng, et al.	3/27/2001

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	PCT	WO 2002/24222 A2	The Cleveland Clinic Foundation	28 March 2002	N/A	
	PCT	WO 2002/092104	Biosynergen, Inc.	21 November 2002	N/A	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	Unknown <b>10/509300</b>	
			Filing Date	September 24, 2004	
			First Named Inventor	Yung-Hi Kim	
			Group Art Unit	Unknown	
			Examiner Name	Unknown	
Sheet	1	of	1	Attorney Docket Number	OPA9408-32/US

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		CARSON M, and LO D, "The Push-Me Pull-You of T Cell Activation" (2001) <i>Science</i> 293:618-619.
		KABAROWSKI JHS, et al., "Lysophosphatidylcholine as a Ligand for the Immunoregulatory Receptor G2A" (2001) <i>Science</i> 293(5530):702-705.
		ZHU K, et al., "Sphingosylphosphorylcholine and Lysophosphatidylcholine Are Ligands for the G Protein-coupled Receptor GPR4" (2001) <i>J. Biol. Chem.</i> 276(44):41325-41335.
		HEERMEIER K, et al., "Oxidized LDL Suppresses NF- $\kappa$ B and Overcomes Protection from Apoptosis in Activated Epithelial Cells" (2001) <i>J. Am. Soc. Nephrol</i> 12:456-463.
		LU, QL, et al., "Mice Lacking the Orphan G Protein-coupled Receptor G2A Develop a Late-Onset Autoimmune Syndrome" (2001) <i>Immunity</i> 14:561-571.
		FUKUSHIMA N, et al. "Lysophospholipid Receptors" (2001) <i>Annu. Rev. Pharmacol. Toxicol.</i> 41:507-534.
		LYNCH KR, et al., "Life on the Edg" (2001) <i>Trends in Pharmacol. Sci.</i> 20(12):473-475.
		XU Y, et al., "Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1" (2000) <i>Nat. Cell. Biol.</i> 2(5):264-267.
		RIKITAKE Y, et al., "Expression of G2A, a Receptor for Lysophosphatidylcholine, by Macrophages in Murine, Rabbit, and Human Atherosclerotic Plaques" (2002) <i>Arterioscler Thromb Vasc Biol.</i> 22:2049-2053.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.